Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 1:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 104 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Mesenchymal stromal cells Clear all
Recruiting Phase 1 Interventional

Adia Med of Winter Park LLC Lower Back Pain Research Study

NCT07587047
View directory record Official record
Conditions
Chronic Mechanical Lower Back Pain, Lower Back Pain, Chronic Lower Back Pain
Interventions
Umbilical Cord Blood-Derived Stem Cells and Exosomes, Placebo IV
Biological · Other
Lead sponsor
Adia Med of Winter Park LLC
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 26, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

Repeated Infusions of Mesenchymal Stromal Cells in Children With Osteogenesis Imperfecta

NCT01061099
View directory record Official record
Conditions
Osteogenesis Imperfecta Type II, Osteogenesis Imperfecta Type III
Interventions
Mesenchymal Stromal Cells
Biological
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 19 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 26, 2026, 1:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

NCT03608631
View directory record Official record
Conditions
KRAS NP_004976.2:p.G12D, Metastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions
Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 26, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

BMT Autologous MSCs for GvHD

NCT02359929
View directory record Official record
Conditions
Graft Versus Host Disease, Acute Graft Versus Host Disease, Chronic Graft Versus Host Disease
Interventions
Autologous mesenchymal stromal cells (MSCs)
Biological
Lead sponsor
Emory University
Other
Eligibility
12 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Sep 26, 2026, 1:14 AM EDT
Terminated No phase listed Observational

Collection of Bone Marrow From Healthy Volunteers and Patients for the Production of Clinical Bone Marrow Stromal Cell (BMSC) Products

NCT01071577
View directory record Official record
Conditions
Bone Marrow Stromal Cells
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 26, 2026, 1:14 AM EDT
Terminated Not applicable Interventional

Autologous Adipose-Derived Stromal Cells Delivered Intra-articularly in Patients With Osteoarthritis.

NCT01739504
View directory record Official record
Conditions
Osteoarthritis
Interventions
Liposuction with Local Anesthesia, Intra articular infusion of AD-SVF
Procedure · Biological
Lead sponsor
Ageless Regenerative Institute
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 26, 2026, 1:14 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of REcycled CartiLage Auto/Allo IMplantation to Treat and Repair Focal Hip Cartilage Defects

NCT05553132
View directory record Official record
Conditions
Cartilage Defect
Interventions
Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier
Combination Product
Lead sponsor
Daniel B. F. Saris
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 26, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome

NCT03818854
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Human Mesenchymal Stromal Cells, Cell Reconstitution Media
Biological
Lead sponsor
Michael A. Matthay
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Sacramento, California • San Francisco, California • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 26, 2026, 1:14 AM EDT
Terminated Phase 1Phase 2 Interventional

Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease

NCT04519671
View directory record Official record
Conditions
Perianal Crohn Disease, Perianal Fistula, Crohn Disease
Interventions
Mesenchymal Stem Cells, Placebo
Drug · Other
Lead sponsor
Anthony Lembo
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 26, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure

NCT02467387
View directory record Official record
Conditions
Non-Ischemic Heart Failure
Interventions
Allogeneic Mesenchymal Bone Marrow Cells (aMBMC), Lactated Ringer's Solution
Drug
Lead sponsor
CardioCell LLC
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Sep 26, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

Tolerance by Engaging Antigen During Cellular Homeostasis

NCT03504241
View directory record Official record
Conditions
Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
Interventions
Donor-derived Mesenchymal Stromal Cells, alemtuzumab, belatacept, sirolimus, mycophenolate mofetil, mycophenolate acid, prednisone
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 26, 2026, 1:14 AM EDT
Recruiting Phase 2 Interventional

Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

NCT06919081
View directory record Official record
Conditions
Persistent Corneal Epithelial Defect, Corneal Epithelial Disorders
Interventions
Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome, Vehicle Control
Drug · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 26, 2026, 1:14 AM EDT
Recruiting Phase 1 Interventional

Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia

NCT06392711
View directory record Official record
Conditions
Xerostomia, Graft-versus-host-disease, Sjogren's Disease
Interventions
Mesenchymal Stromal Cells (MSC) Dose Level 0, Mesenchymal Stromal Cells (MSC) Dose Level 1
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 26, 2026, 1:14 AM EDT
Active, not recruiting Phase 3 Interventional

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)

NCT05838092
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
allo-APZ2-OTS, Placebo
Drug
Lead sponsor
RHEACELL GmbH & Co. KG
Industry
Eligibility
6 Months and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 26, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

NCT04466098
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia
Interventions
Mesenchymal stromal cells, Placebo
Biological · Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Minneapolis, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Sep 26, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines

NCT02408432
View directory record Official record
Conditions
Cardiomyopathy, Heart Failure
Interventions
Laboratory Biomarker Analysis, Standard of Care, Mesenchymal Stem Cell Transplantation
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Sep 26, 2026, 1:14 AM EDT
Recruiting Phase 1 Interventional

UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients

NCT06737380
View directory record Official record
Conditions
SLE, Lupus, Systemic Lupus Erthematosus, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE)
Interventions
Physical examination, Electrocardiogram, SF-36 questionnaire, Clinical laboratory evaluations - Serology, Clinical laboratory evaluations - Biochemistry, Clinical laboratory evaluations - Hematology, Pregnancy Test, Urinalysis, SLE activity evaluation, SLE biomarker profiling, Cytokines and chemokine profiling, single dose of UC-MSCs, PROMIS instruments
Diagnostic Test · Other · Biological
Lead sponsor
LiveKidney.Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 26, 2026, 1:14 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy

NCT04445220
View directory record Official record
Conditions
COVID-19, Acute Kidney Injury, Sepsis
Interventions
SBI-101
Biological
Lead sponsor
Sentien Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Albuquerque, New Mexico • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Sep 26, 2026, 1:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)

NCT04345601
View directory record Official record
Conditions
Sars-CoV2, Acute Respiratory Distress Syndrome, COVID-19
Interventions
Mesenchymal Stromal Cells, Supportive Care
Biological · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 26, 2026, 1:14 AM EDT
Completed Phase 1 Interventional Results available

Open Label Phase I hCT-MSC in Toddlers With Autism Spectrum Disorder

NCT04294290
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
hCT-MSC infusion
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Months to 48 Months
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 26, 2026, 1:14 AM EDT
No Longer Available No phase listed Expanded access

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection

NCT04366830
View directory record Official record
Conditions
Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19
Interventions
Remestemcel-L
Drug
Lead sponsor
Mesoblast International Sàrl
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 26, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

hCT-MSCs for Children With Autism Spectrum Disorder (ASD)

NCT03099239
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder, ASD
Interventions
hCT-MSC infusion
Biological
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
2 Years to 11 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Sep 26, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

Autologous Culture Expanded Mesenchymal Stromal Cells for Knee Osteoarthritis

NCT02805855
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Autologous Adipose-Derived Mesenchymal Stromal Cells
Drug
Lead sponsor
Jacob L. Sellon, M.D.
Other
Eligibility
40 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Sep 26, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

Stem Cell Fistula Plug in Perianal Crohn's Disease

NCT01915927
View directory record Official record
Conditions
Perianal Crohn's Disease
Interventions
MSC-AFP
Drug
Lead sponsor
William A. Faubion, M.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Sep 26, 2026, 1:14 AM EDT